




Am ndments

Please amend claims 1 and 20 as follows:

1 (amended). A compound of the formula:




wherein

n is 1 or 2;

R²⁸ and **R**⁴³ are independently selected from the group consisting of H and a substituted or unsubstituted aliphatic or acyl moiety;

one of **R**^{7a} and **R**^{7b} is H and the other is halo, -**R**^A, -**OR**^A, -**SR**^A, -**OC(O)R**^A, -**OC(O)NR**^A**R**^B, -**N****NR**^A**R**^B, -**NR**^B**C(O)R**^A, -**NR**^B**C(O)OR**^A, -**NR**^B**SO**₂**R**^A or -**NR**^B**SO**₂**NR**^A**R**^B; or **R**^{7a} and **R**^{7b}, taken together, are H in the tetraene moiety:



where **R**^A is H or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety and where **R**^B is H, OH or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety; **r a**

[as a substantially pure stereoisomer or mixture of stereoisomers, and as an] pharmaceutically acceptable derivative thereof.

RECEIVED

JAN 09 2002

TECH CENTER 1600/2900

